Prophylaxis News and Research

RSS

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Baxter International Inc. today announced that the company has submitted a biologics license application to the United States Food and Drug Administration for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B.

From Baxter International Inc. 5 Sep 2012

Study assesses post-coronary artery bypass graft surgery atrial fibrillation and long-term survival

Atrial fibrillation is a common complication of cardiac surgery, occurring in 10 percent to 40 percent of patients. Recent studies show it to be associated with poorer health following surgery and poorer long-term survival. Furthermore, development of atrial fibrillation after cardiac surgery leads to average additional health care costs of $15,000 to $20,000.

1 Sep 2012

FDA approves Gilead’s Stribild to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

28 Aug 2012

Pre-emptive therapy better than valacyclovir prophylaxis in treating CMV in transplant recipients

Waiting to treat the commonest viral infections in transplant recipients until they reach a certain threshold is better than prophylactically treating all recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

24 Aug 2012

International community must redouble efforts to ensure 'many' AIDS-free generations

A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia.

22 Aug 2012

Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection

Genocea Biosciences announced today that it has initiated a Phase 1/2a clinical study with its lead candidate, GEN-003. GEN-003 is an investigational vaccine designed to stimulate T cell and B cell immune responses to potentially reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe Herpes Simplex Virus type 2 (HSV-2) infection.

16 Aug 2012

Tranexamic acid reduces bleeding in off-pump coronary bypass surgery

Patients undergoing off-pump coronary artery bypass grafting who are given a tranexamic acid infusion show a modest reduction in postoperative bleeding and blood transfusion relative to their placebo-treated peers, a clinical trial shows.

15 Aug 2012

Women with chronic PVT should be informed, not discouraged, about pregnancy

Maternal and fetal outcomes are favorable for most pregnancies that reach 20 weeks’ in women with chronic portal vein thrombosis, a study shows.

13 Aug 2012

Pre-cesarean antibiotics cut infection risk

Administering prophylactic antibiotics before women undergo cesareans significantly reduces postsurgical infection rates, show US study findings.

9 Aug 2012

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

A pivotal clinical trial for an anti-rabies human monoclonal antibody (RMAb) being developed through a collaborative partnership between MassBiologics of the University of Massachusetts Medical School and the Serum Institute of India, Ltd., is starting to enroll patients.

8 Aug 2012

Mylan receives final FDA approval for Montelukast Sodium Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg, the generic version of Merck's Singulair Tablets.

7 Aug 2012

Access to dental care alone is not sufficient to meet oral health needs of adults with I/DD

A comprehensive study using electronic dental records to profile the oral health status of adults with intellectual and developmental disabilities (I/DD) has concluded that access to specialized dental care alone is not sufficient to meet the community's substantial oral health needs.

2 Aug 2012

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

31 Jul 2012

GlobalPost examines debate surrounding PrEP

GlobalPost's "Global Pulse" blog examines questions surrounding the use of the antiretroviral Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at high risk, as studies released and panel discussions held last week at the XIX International AIDS Conference (AIDS 2012) "raised concerns about the drug's effect on the future of the AIDS fight."

31 Jul 2012

Views on AIDS: More funding will be needed for new attack on HIV; The epidemic hits hard in the South

The international AIDS conference in Washington has already made two points clear. There is no prospect that scientists will any time soon find the ultimate solutions to the AIDS epidemic, namely a vaccine that would prevent infection with the AIDS virus or a "cure" for people already infected with the virus.

31 Jul 2012

Prophylaxis News and Research

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Study assesses post-coronary artery bypass graft surgery atrial fibrillation and long-term survival

FDA approves Gilead’s Stribild to treat HIV-1 infection

Pre-emptive therapy better than valacyclovir prophylaxis in treating CMV in transplant recipients

International community must redouble efforts to ensure 'many' AIDS-free generations

Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection

Tranexamic acid reduces bleeding in off-pump coronary bypass surgery

Women with chronic PVT should be informed, not discouraged, about pregnancy

Pre-cesarean antibiotics cut infection risk

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

Mylan receives final FDA approval for Montelukast Sodium Tablets ANDA

Access to dental care alone is not sufficient to meet oral health needs of adults with I/DD

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

GlobalPost examines debate surrounding PrEP

Views on AIDS: More funding will be needed for new attack on HIV; The epidemic hits hard in the South

Enoxaparin prevents PVT in advanced cirrhosis

Letter to the editor: The role for pre-exposure prophylaxis in the fight against AIDS

HIV drug resistance: an interview with Dr. Silvia Bertagnolio

HPTN study results show additional benefits of early ART in HIV clinical outcomes

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News